Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Investing Activities (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Cash from Investing Activities for 16 consecutive years, with -$856665.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 599.42% year-over-year to -$856665.0, compared with a TTM value of -$1.5 million through Oct 2025, down 7.75%, and an annual FY2025 reading of -$1.5 million, down 7.75% over the prior year.
  • Cash from Investing Activities was -$856665.0 for Q4 2025 at Pharma-Bio Serv, down from $1.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $7.3 million in Q4 2023 and bottomed at -$8.2 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is -$288407.0, with a median of -$1385.5 recorded in 2022.
  • Peak annual rise in Cash from Investing Activities hit 65099.47% in 2023, while the deepest fall reached 1199309.94% in 2023.
  • Year by year, Cash from Investing Activities stood at $881.0 in 2021, then tumbled by 1477.64% to -$12137.0 in 2022, then soared by 60469.54% to $7.3 million in 2023, then crashed by 97.66% to $171532.0 in 2024, then plummeted by 599.42% to -$856665.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for PBSV at -$856665.0 in Q4 2025, $1.6 million in Q3 2025, and -$3.2 million in Q2 2025.